Established in 1896 and headquartered in Basel, Switzerland, Roche has business operations in more than 150 countries and has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics.
Based on the strategic alliance with Roche, Chugai Pharmaceutical Co., Ltd. merged with Nippon Roche, and Roche acquired a majority of Chugai Pharmaceutical Co., Ltd.’s stock. Roche holds 59.89% of Chugai Pharmaceutical Co., Ltd.’s outstanding shares and Chugai Pharmaceutical Co., Ltd. adopted a new business model. Under this model, Chugai Pharmaceutical Co., Ltd. maintained both its name, CEO, and management autonomy, and both parties agreed to keep Chugai Pharmaceutical Co., Ltd. as a listed company on the Prime Market of the Tokyo Stock Exchange.*
*Information accurate as of August 2023.
The strategic alliance provides Chugai Pharmaceutical Co., Ltd. with exclusive rights to develop and market Roche products in Japan. In addition, Chugai Pharmaceutical Co., Ltd. gains access to a worldwide footprint for its in-house products by out-licensing them to Roche, who can then market them to their global market.
For some of the Chugai Pharmaceutical Co., Ltd. assets out-licensed to Roche, the companies enter into a co-promote, or promotion service, relationship in Europe. As a result, in our core areas of haemophilia, oncology and rheumatology, our European team works closely with their Roche colleagues to deliver products to the medical community across France, Germany, and the UK.
We are proud of our partnership with Roche in Europe, supporting collaborative teams that can achieve more for patients.
C-GB-00000896 | Date of Preparation: November 2023
